1	Avoiding false positive SARS-CoV-2 rapid antigen test results with point-of-care molecular testing on							
2		residual test buffer						
3	Jason J LeBlanc ^{a,b,c,d} * Gregory	R. McCracken ^ª , Barbara Goodall ^C , Todd F Hatchette ^{a,b,c,d} , Lisa Barrett ^{a,b,c,d} ,						
4	ohn Ross ^e , Ross J Davidson ^{a,b,c,d} , Glenn Patriquin ^{a,b}							
5	^a Division of Microbiology, Dep	Aicrobiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health,						
6	Halifax, Nova Scotia, Canada.							
7	^b Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.							
8	^c Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.							
9	^d Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.							
10	^e Praxes Medical Group, Halifax, Nova Scotia, Canada.							
11								
12	Key Words: COVID-19, SARS-CoV-2, rapid, antigen, buffer, false positive, PCR, POC, residual, specificity							
13	Running title: SARS-CoV-2 confirmation from rapid test buffer							
14								
15	Word count: 1196; Abstract: 250							
16								
17	*Corresponding author:	Jason J. LeBlanc, PhD, FCCM, d(ABMM),						
18		Division of Microbiology, Department of Pathology and Laboratory						
19		Medicine, Nova Scotia Health (NSH),						
20		Room 404B, MacKenzie Building,						
21		5788 University Avenue, Halifax, Nova Scotia, B3H 1V8						
22		Tel.: +1 902 473 7698; Fax: +1 902 473 7971						
23		Email: jason.leblanc@cdha.nshealth.ca						

24 Abstract

Objectives: Antigen-based rapid diagnostic tests (Ag-RDTs) have been widely used for the detection of SARS-CoV-2 during the Covid-19 pandemic. In settings of low disease prevalence, such as asymptomatic community testing, national guidelines recommend molecular confirmation of positive Ag-RDT results. This often requires patients to be recalled for repeat specimen recollection and subsequent testing in reference laboratories. This project assessed the use of a point-of-care molecular method for SARS-CoV-2 detection on-site at a volunteer-led asymptomatic community testing site, using the residual test buffer (RTB) from positive Ag-RDTs.

Methods: The Abbott COVID-19 ID NOW assay was performed on RTB from two Ag-RDTs: the Abbott Panbio COVID-19 Ag Rapid Test Device and the BTNX Rapid Response COVID-19 Antigen Rapid Test Device. All RTBs were tested using real-time RT-PCR at a reference laboratory using the ThermoFisher TaqPath COVID-19 Combo kit which was used to assign positive Ag-RDTs results as true or false positives. Analytical specificity of the ID NOW was assessed with a panel of various respiratory organisms.

Results: Of 419 positive Ag-RDTs from 5148 tests performed, ID NOW testing of the RTB was positive in
 100% of the samples characterized as true positives by RT-PCR. No SARS-CoV-2 detections by ID NOW
 were observed from 10 specimens characterized as false positive Ag-RDTs, or from contrived specimens
 with various respiratory organisms.

42 **Conclusions:** The use of on-site molecular testing on RTB provides a suitable option for rapid 43 confirmatory testing of positive Ag-RDTs, thereby obviating the need for specimen recollection for 44 molecular testing at local reference laboratories.

45

46

47 Introduction

With their simplicity, speed, and scalability, antigen-based rapid diagnostic tests (Ag-RDTs) have been 48 deployed worldwide to facilitate SARS-CoV-2 detection.¹⁻⁵ Ag-RDT positive results has been associated 49 50 with the ability to culture SARS-CoV-2 in vitro or viral loads consistent with transmissible virus; therefore, Ag-RDTs has been used as a surrogate for SARS-CoV-2 communicability.⁶⁻¹⁰ Nova Scotia was 51 52 the first Canadian province to implement Ag-RDTs for self-perceived asymptomatic individuals in low-53 barrier volunteer-led community testing centres, to identify individuals at high risk of transmitting SARS-CoV-2 that might otherwise have gone unnoticed.^{11,12} Following national guidelines, individuals with 54 positive Ag-RDTs were asked to return to testing centres for specimen recollection, and confirmatory 55 56 testing using nucleic acid amplification tests (NAATs) performed at local reference laboratories. To 57 streamline confirmation of positive Ag-RDTs, direct NAAT testing on the Ag-RDT residual test buffer 58 (RTB) was evaluated.

Like others¹³, our previous study demonstrated high sensitivity for SARS-CoV-2 detection using RTB from 59 nasopharyngeal and nasal swab collections.¹¹ RTB obviated the need for specimen recollection for 60 NAAT-based confirmation of Ag-RDT results, but RTB processing remained at the reference laboratory. 61 62 To further optimize community testing strategies, this project evaluated a portable NAAT-based rapid 63 diagnostic test (NAAT-RDT) for on-site confirmation of Ag-RDTs-positive results at the community testing centers. The COVID-19 assay on the Abbott ID NOW instrument is an NAAT-RDT that uses isothermal 64 technology that is amenable to point-of-care applications.⁴ This NAAT-RDT is simple and provides rapid 65 66 results with high sensitivity and specificity, but its single-specimen processing limits its scalability for testing large populations.¹⁴⁻¹⁶ Instead, this NAAT-RDT was evaluated for rapid confirmation of SARS-CoV-67 68 2 using RTB from positive Ag-RDTs, at the site of sample collection (Table 1).

69 The assessment was performed in two stages on asymptomatic individuals presenting to urban rapid testing sites. The first overlapping with the ISNOT project (designed to compare SARS-CoV-2 Ag-RDT 70 results from self-administered nasal and throat collections)¹² (Table S1 and S2), and the second was an 71 72 extension of the project where additional positive Ag-RDT RTBs were tested over a subsequent two-73 week period (Table S3). In both cases, Ag-RDT self-testing using the Panbio COVID-19 Ag Rapid Test Device (Abbott Rapid Diagnostics, Jena, Germany) or the Rapid Response COVID-19 Antigen Rapid Test 74 75 Device (BTNX Inc., Markham, ON) was used. Ag-RDTs were interpreted according to manufacturer instructions, and SARS-CoV-2 target bands were graded with scores of 0 (negative), +/- (barely visible), 76 77 or 1+, 2+ or 3+ relative to the intensity of the control band. RTB from either Ag-RDT were subjected to 78 two NAATs. The COVID-19 ID Now assay (Abbott Diagnostics, Scarborough, MA) was performed on-site 79 following manufacturer instructions, except two drops of RTB that were added to the sample chamber 80 prior to processing the original Ag-RDT collection swab. The remaining RTB and swab were transported 81 to a central laboratory in the Ag-RDT reaction tube, and 200 µl of viral transport medial (VTM) 82 (Rodoxica, Little Rock, AR) was added to the tube. Following vortexing for 10 seconds, 200 µl of 83 VTM/RTB fluid was subjected to a total nucleic acid extraction (TNA) on a MagNA Pure 96 or LC 2.0 84 instrument (Roche Diagnostics ltd., Roltkreuz, Switzerland), and 5 μ l of the 50 μ l of eluted TNAs were 85 used as template for real-time RT-PCR using the TaqPath COVID-19 Combo Kit (Life Technologies Corp., 86 Frederick, MD).

Of 1472 individuals who consented to the ISNOT project¹², 159 and 58 were positive using the Panbio (Table 1) and BTNX (Table S1) Ag-RDTs, respectively. The ID NOW was positive for all Ag-RDT positive RTB samples, regardless of anatomical site of collection, Ag-RDT method used, antigen score, or RT-PCR threshold cycle (Ct) value (Tables S1 and S2). No false positives were identified, suggesting high specificity. This data supports use of the NAAT-RDT to quickly rule-in SARS-CoV-2 using RTB from positive Ag-RDTs, thereby ruling out false positive Ag-RDT reactions. However, further testing was

93 needed to verify if false positive Ag-RDTs would be negative with the ID NOW assay. First, highly 94 concentrated nucleic acids from various respiratory microorganisms were spiked into 300 µl Panbio 95 buffer and tested with the ID NOW assay. The assay detected a variety of SARS-CoV-2 lineages, but no 96 cross-reactions were observed with other respiratory organisms (Table S4). Then, for two weeks following the ISNOT project, RTB from positive Ag-RDT reactions were subjected to ID NOW and RT-PCR 97 98 testing (Table S3). Of 3676 individuals tested, 147 had positive Ag-RDTs, and 137 were positive for both 99 ID NOW and RT-PCR. There were 10 false positive Ag-RDTs compared to RT-PCR, and these were also negative by ID NOW. Consistent with our previous study¹¹, false positive Ag-RDTs were described as 100 101 having barely visible target bands, with antigen scores +/- or 1+. The proportion of false positives 102 observed (10/3676 or 0.3%) is consistent with manufacturer and literature claims, where false positive reactions are rare at approximately 0.4%^{18,19}. 103

104 Specificity was the focus for the intended use of the ID NOW in this investigation. Sensitivity analyses 105 would require IDNOW and RT-PCR testing on all Ag-RDT RTB negative specimens, which would not 106 typically be performed in community-based surveillance. Some sensitivity data was captured during the ISNOT guality initiative¹², as the ID NOW was performed in parallel on Ag-RDT RTB from paired swabs 107 108 samples from positive individuals. As such, some specimens were negative by Ag-RDT for one swab type 109 of the paired collection, but positive results were obtained by ID NOW and/or RT-PCR. While Ag-RDTs 110 appear less sensitive than NAATs (as seen in Tables S1 and S2), it has been argued that the additional 111 detections by NAATs often represent remnant RNA from resolved infections, when the risk for transmission is low.²⁰⁻²³ Alternatively, it may represent periods of early infection that are short-lived in 112 population-based testing and can be mitigated by frequent testing over time with Ag-RDTs.²⁰⁻²³ 113 114 Importantly, ID NOW confirmed all true positive Ag-RDTs, as well as detected 88.2% (30/34) and 85.7% (18/21) of negative Panbio and BTNX Ag-RDT RTBs that tested positive by RT-PCR, respectively (Tables 115 116 S1 and S2). Discrepant results between ID NOW and RT-PCR were in specimens with Ct values \geq 30,

suggesting low viral loads. Altogether, the ID NOW was found to be sufficiently sensitive to be used as aconfirmatory method for Ag-RDTs.

119 Overall, ID NOW confirmed 409 true positive Ag-RDT results, ruled out 10 false positives, and there was 120 no cross-reactivity with other respiratory organisms. The applications of rapid NAAT-RDT confirmation 121 of positive Ag-RDTs on-site using RTB obviates the need for individuals to return for repeat specimen 122 collection for NAAT testing at local reference laboratories, as well as the need for trained personnel for 123 shipping biological samples to reference laboratories. With recent surges of SARS-CoV-2 activity with the 124 highly transmissible Omicron variant, many clinical laboratories were overwhelmed with high testing 125 demands, hampering their ability to support confirmation for Ag-RDT-positive results. Given wide 126 community spread, and the low proportion of false positive results during this period of high disease 127 prevalence, NAAT-based confirmation of Ag-RDT results was not prioritized. However, in the wake of 128 pandemic waves as disease prevalence decreases, the possibility of false positive Ag-RDT increases and confirmatory testing for Ag-RDT will again become important to consider.^{24,25} The use of RTB testing 129 130 with NAAT-RDTs provides a feasible and accurate option for rapid confirmatory testing of positive Ag-131 RDTs at community testing sites.

132 Acknowledgements

The authors are indebted to the community participants for this evaluation, and to the many Test-to-Protect volunteers and coaches who have worked countless hours throughout the pandemic to ensure the safety of their community and community members. The authors would also like to thank the clinical laboratories across Nova Scotia, who have supported confirmation of Ag-RDTs results throughout the pandemic.

138 Funding

The authors declare that they have no conflicts of interest. This work received no private or public funding, except for the Ag-RDT kits that were provided in-kind from the government of Canada. RT-PCR testing was provided in-kind by the Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health.

143 Ethics

This project was deemed a quality initiative and was therefore exempt from review by the Nova Scotia Health Research Ethics Board (submission number 1027644). Specimens tested were obtained from consenting participants, and all data related were provided anonymized, de-identified, and were used solely with the intent to evaluate the performance characteristics of the different swab types for rapid antigen testing programs used in Nova Scotia.

149 **Author contributions**

150 All authors were involved in the design, data acquisition, and data interpretation. JL, GP, and TH drafted

151 the initial manuscript, with all authors contributing, and agree with the content of the final version.

152 References

153 1. Matsuda EM, de Campos IB, de Oliveira IP, Colpas DR, Carmo AMDS, Brígido LFM. Field evaluation of

154 COVID-19 antigen tests versus RNA based detection: Potential lower sensitivity compensated by

immediate results, technical simplicity, and low cost. J Med Virol. 2021;93(7):4405-4410. doi:

- 156 10.1002/jmv.26985. PMID: 33788270; PMCID: PMC8250877.
- Schwartz KL, McGeer AJ, Bogoch II. Rapid antigen screening of asymptomatic people as a public
 health tool to combat COVID-19. CMAJ. 2021;193(13):E449-E452. doi: 10.1503/cmaj.210100. PMID:
 33658247; PMCID: PMC8099167.

Pavelka M, Van-Zandvoort K, Abbott S, Sherratt K, Majdan M; CMMID COVID-19 working group;
 Inštitút Zdravotných Analýz, Jarčuška P, Krajčí M, Flasche S, Funk S. The impact of population-wide
 rapid antigen testing on SARS-CoV-2 prevalence in Slovakia. Science. 2021;372(6542):635-641. doi:
 10.1126/science.abf9648. PMID: 33758017; PMCID: PMC8139426.

Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, Oyewunmi OD, Camargo C, Nikpour B, Armanfard N, Sagan SM,
 Jahanshahi-Anbuhi S. Tools and techniques for severe acute respiratory syndrome coronavirus 2
 (SARS-CoV-2)/COVID-19 detection. Clin Microbiol Rev. 2021;34(3):e00228-20. doi:
 10.1128/CMR.00228-20. PMID: 33980687; PMCID: PMC8142517.

Martín-Sánchez V, Fernández-Villa T, Carvajal Urueña A, Rivero Rodríguez A, Reguero Celada S,
 Sánchez Antolín G, Fernández-Vázquez JP. Role of rapid antigen testing in population-based SARS CoV-2 screening. J Clin Med. 2021;10(17):3854. doi: 10.3390/jcm10173854. PMID: 34501297;
 PMCID: PMC8432187.

Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, Boodman C, Bello A, Hedley A, Schiffman
 Z, Doan K, Bastien N, Li Y, Van Caeseele PG, Poliquin G. Predicting infectious severe acute respiratory
 syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis. 2020;71(10):2663-2666. doi:
 10.1093/cid/ciaa638. PMID: 32442256; PMCID: PMC7314198.

Pekosz A, Parvu V, Li M, Andrews JC, Manabe YC, Kodsi S, Gary DS, Roger-Dalbert C, Leitch J, Cooper
 CK. Antigen-based testing but not real-time polymerase chain reaction correlates with severe acute
 respiratory syndrome coronavirus 2 viral culture. Clin Infect Dis. 2021;73(9):e2861-e2866. doi:
 10.1093/cid/ciaa1706. PMID: 33479756; PMCID: PMC7929138.

Pickering S, Batra R, Merrick B, Snell LB, Nebbia G, Douthwaite S, Reid F, Patel A, Kia lk MT, Patel B,
 Charalampous T, Alcolea-Medina A, Lista MJ, Cliff PR, Cunningham E, Mullen J, Doores KJ, Edgeworth
 JD, Malim MH, Neil SJD, Galão RP. Comparative performance of SARS-CoV-2 lateral flow antigen
 tests and association with detection of infectious virus in clinical specimens: a single-centre

184 laboratory evaluation study. Lancet Microbe. 2021;2(9):e461-e471. doi: 10.1016/S2666185 5247(21)00143-9.

Kohmer N, Toptan T, Pallas C, Karaca O, Pfeiffer A, Westhaus S, Widera M, Berger A, Hoehl S,
 Kammel M, Ciesek S, Rabenau HF. The comparative clinical performance of four SARS-CoV-2 rapid
 antigen tests and their correlation to infectivity in vitro. J Clin Med. 2021;10(2):328. doi:
 10.3390/jcm10020328. PMID: 33477365; PMCID: PMC7830733.

190 10. Tariq M, Kim DM, Kim CM, Bang MS, Lee YM, Seo JW, Kim DY, Yun NR. Viable severe acute 191 respiratory syndrome coronavirus 2 isolates exhibit higher correlation with rapid antigen assays than 192 subgenomic RNA genomic RNA. Front Microbiol. 2021;12:718497. doi: or 193 10.3389/fmicb.2021.718497. PMID: 34867844; PMCID: PMC8633410.

11. Patriquin G, LeBlanc JJ, Williams C, Hatchette TF, Ross J, Barrett L, Davidson R. Comparison between
 nasal and nasopharyngeal swabs for SARS-CoV-2 rapid antigen detection in an asymptomatic
 population, and direct confirmation by RT-PCR from the residual buffer. Microbiol Spectr. 2022 Feb
 16:e0245521. doi: 10.1128/spectrum.02455-21. PMID: 35171010.

198 12. Goodall B, LeBlanc JJ, Hatchette TF, Barrett L, Patriquin G. Investigating sensitivity of nasal or throat

199 (ISNOT): A combination of both swabs increases sensitivity of SARS-CoV-2 rapid antigen tests.

200 medRxiv 2022.01.18.22269426; doi: <u>https://doi.org/10.1101/2022.01.18.22269426</u>. [submitted to
 201 Microbiology Spectrum, Spectrum00217-22]

13. Castineiras TMPP, Nascimento ÉRDS, Faffe DS, Galliez RM, Mariani D, Leitão IC, de Melo MGM,
Ferreira OC, Tanuri A; UFRJ COVID-19 Working group. Performance of an alternative RT-PCR
procedure using residual sample from the Panbio Ag COVID-19 test. Braz J Infect Dis.
205 2021;25(5):101630. doi: 10.1016/j.bjid.2021.101630. PMID: 34648741; PMCID: PMC8506141.

14. Ramachandran A, Noble J, Deucher A, Miller S, Tang PW, Wang RC. Performance of Abbott ID-Now
 rapid nucleic amplification test for laboratory identification of COVID-19 in asymptomatic

208 emergency department patients. J Am Coll Emerg Physicians Open. 2021;2(6):e12592. doi:
 209 10.1002/emp2.12592. PMID: 35005704; PMCID: PMC8716572.

Stokes W, Berenger BM, Singh T, Adeghe I, Schneider A, Portnoy D, King T, Scott B, Pabbaraju K,
Shokoples S, Wong AA, Gill K, Turnbull L, Hu J, Tipples G. Acceptable performance of the Abbott ID
NOW among symptomatic individuals with confirmed COVID-19. J Med Microbiol.
2021;70(7):001372. doi: 10.1099/jmm.0.001372. PMID: 34309503; PMCID: PMC8493423.

21416. Smithgall MC, Scherberkova I, Whittier S, Green DA. Comparison of Cepheid Xpert Xpress and215Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2. J Clin Virol. 2020;128:104428.

216 doi: 10.1016/j.jcv.2020.104428. PMID: 32434706; PMCID: PMC7217789.

17. Graham M, Muhi S, Hoang T, Ballard SA, McAuley J, Kwong JC, Williamson DA, Howden BP; COVID19 Diagnostics Research Group. Multi-site point of care assessment of Abbott ID NOW rapid
molecular test for SARS-CoV-2 in a low-prevalence setting. Pathology. 2021;53(7):912-914. doi:
10.1016/j.pathol.2021.07.002. PMID: 34561096; PMCID: PMC8416649.

18. Patriquin G, Davidson RJ, Hatchette TF, Head BM, Mejia E, Becker MG, Meyers A, Sandstrom P,
Hatchette J, Block A, Smith N, Ross J, LeBlanc JJ. Generation of false-positive SARS-CoV-2 antigen
results with testing conditions outside manufacturer recommendations: A scientific approach to
pandemic misinformation. Microbiol Spectr. 2021;9(2):e0068321. doi: 10.1128/Spectrum.00683-21.
Epub 2021 Oct 20. PMID: 34668722; PMCID: PMC8528119.

19. Hledík M, Polechová J, Beiglböck M, Herdina AN, Strassl R, Posch M. Analysis of the specificity of a
 COVID-19 antigen test in the Slovak mass testing program. PLoS One. 2021;16(7):e0255267. doi:
 10.1371/journal.pone.0255267. PMID: 34324553; PMCID: PMC8320988.

229 20. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, Tambe M, Mina MJ, Parker R. Test
 230 sensitivity is secondary to frequency and turnaround time for COVID-19 screening. Sci Adv.
 231 2021;7(1):eabd5393. doi: 10.1126/sciadv.abd5393. PMID: 33219112; PMCID: PMC7775777.

232 21. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 test sensitivity - A strategy for containment.
233 N Engl J Med. 2020;383(22):e120. doi: 10.1056/NEJMp2025631. PMID: 32997903.

22. Chin ET, Huynh BQ, Chapman LAC, Murrill M, Basu S, Lo NC. Frequency of routine testing for
coronavirus disease 2019 (COVID-19) in high-risk healthcare environments to reduce outbreaks. Clin
Infect Dis. 2021;73(9):e3127-e3129. doi: 10.1093/cid/ciaa1383. PMID: 33570097; PMCID:
PMC7797732.

238 23. Patriquin G, LeBlanc JJ. SARS-CoV-2 sensitivity limbo - How low can we go? Int J Infect Dis.
 239 2021;103:23-24. doi: 10.1016/j.ijid.2020.11.138. PMID: 33212261; PMCID: PMC7669480.

240 24. Skittrall JP, Wilson M, Smielewska AA, Parmar S, Fortune MD, Sparkes D, Curran MD, Zhang H, Jalal

- H. Specificity and positive predictive value of SARS-CoV-2 nucleic acid amplification testing in a lowprevalence setting. Clin Microbiol Infect. 2021;27(3):469.e9-469.e15. doi:
- 243 10.1016/j.cmi.2020.10.003. PMID: 33068757; PMCID: PMC7554481.

244 25. Jüni P, Baert S, Corbeil A, Johnstone J, Patel SN, Bobos P, Upton A, Barrett KA, Barrett LL, Bodmer

245 NS, Born KB, Bourns L, Evans GA, Hopkins J, Manuel DG, Morris AM, Razak F, Sander B, Science M,

246 Steiner R, Tepper J, Thampi N, McGeer A, on behalf of the Ontario COVID-19 Science Advisory Table.

247 Use of rapid antigen tests during the omicron wave. Science Briefs of the Ontario COVID-19 Science

Advisory Table. 2022;3(56). <u>https://doi.org/10.47326/ocsat.2022.03.56.1.0</u> [last accessed Feb 17,

249 2022].

Table 1. Summary of ID NOW results from all study phases.

Category			ID NOW results*			
			Nasal (n=164)	Throat	Combined nasal/throat	Total (n=419)
	Ag+/NAAT+		100.0% (132/132)	100.0% (66/66)	100% (156/156)	100.0% (354/354)
Antigen status	Ag+/NAAT-		0.0% (0/4)	N/A	0.0% (0/6)	0.0% (0/10)
	Ag-/NAAT+		82.1% (23/28)	92.6% (25/27)	N/A	87.3% (48/55)
	Ag+/NAAT+	3+	100.0% (32/32)	100.0% (13/13)	100.0% (41/41)	100.0% (86/86)
		2+	100% (43/43)	100.0% (22/22)	100.0% (52/52)	100.0% (117/117)
Antigon cooro		1+	100.0% (36/36)	100.0% (19/19)	100.0% (33/33)	100.0% (88/88)
Antigen score		+/-	100.0% (21/21)	100.0% (12/12)	100.0% (30/30)	100.0% (63/63)
	Ag+/NAAT-	1+	0.0% (0/1)	N/A	0.0% (0/2)	0.0% (0/3)
		+/-	0.0% (0/3)	N/A	0.0% (0/4)	0.0% (0/7)
	Ag+/NAAT+	<25	100.0% (28/28)	100.0% (6/6)	100.0% (62/62)	100.0% (96/96)
		25 to <30	100.0% (58/58)	100.0% (30/30)	100.0% (68/68)	100.0% (156/156)
Ct value**		≥30	100.0% (46/46)	100.0% (30/30)	100.0% (26/26)	100.0% (102/102)
	Ag-/NAAT+	25 to <30	N/A	100.0% (4/4)	N/A	100.0% (4/4)
		≥30	82.1% (23/28)	91.3% (21/23)	N/A	86.3% (44/51)

*ID Now for individual test and project phases are provided in Tables S1, S2, and S3. **Ct values were categorized based on the N gene of the TaqPath real-time RT-PCR. Abbreviations: antigen (Ag); antigen-based rapid diagnostic test (Ag-RDT); threshold cycle (Ct); nucleic acid amplification test (NAAT); residual test buffer (RTB).